These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7908898)

  • 1. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
    Lipponen P; Eskelinen M; Hietala K; Syrjänen K; Gambetta RA
    Int J Cancer; 1994 Apr; 57(2):275-80. PubMed ID: 7908898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of p53 protein, c-erbB-2 protein, epidermal growth factor receptor protein and proliferating cell nuclear antigen in gastric carcinoma.
    Jang WI; Yang WI; Lee CI; Kim HS; Song KS; Cho MY; Park JK; Shim YH
    J Korean Med Sci; 1993 Aug; 8(4):293-304. PubMed ID: 7911025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.
    Vesalainen SL; Lipponen PK; Talja MT; Alhava EM; Syrjänen KJ
    Int J Cancer; 1994 Jul; 58(2):303-8. PubMed ID: 7913085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
    Lipponen P; Eskelinen M
    Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameter.
    Hasebe T; Mukai K; Yamaguchi N; Ishihara K; Kaneko A; Takasaki Y; Shimosato Y
    Mod Pathol; 1994 Jan; 7(1):37-43. PubMed ID: 7909154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.
    Shrestha P; Yamada K; Wada T; Maeda S; Watatani M; Yasutomi M; Takagi H; Mori M
    Virchows Arch A Pathol Anat Histopathol; 1992; 421(3):193-202. PubMed ID: 1357812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrelationship between expression of p53, proliferating cell nuclear antigen and c-erbB-2 in bladder cancer.
    Lipponen PK
    Pathobiology; 1993; 61(3-4):178-82. PubMed ID: 8105802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.
    Kamio N
    Virchows Arch; 1996 May; 428(2):75-83. PubMed ID: 8925128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma.
    Lipponen P; Eskelinen M; Syrjänen K
    Br J Cancer; 1995 Apr; 71(4):863-7. PubMed ID: 7710955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.
    Fléjou JF; Paraf F; Muzeau F; Fékété F; Hénin D; Jothy S; Potet F
    J Clin Pathol; 1994 Jan; 47(1):23-6. PubMed ID: 7907608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
    J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma.
    Sun XF; Carstensen JM; Stål O; Zhang H; Nordenskjöld B
    Int J Cancer; 1996 Feb; 69(1):5-8. PubMed ID: 8600060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade.
    Nielsen AL; Nyholm HC
    Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(1):79-85. PubMed ID: 9031925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells.
    Sasano H; Date F; Imatani A; Asaki S; Nagura H
    Hum Pathol; 1993 Jun; 24(6):584-9. PubMed ID: 8099338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.